Order Article Reprints

Sanghvi VR, Mohan P, Singh K, Cao L, Berishaj M, Wolfe AL, Schatz JH, Lailler N, de Stanchina E, Viale A, et al. NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. Cancers. 2021; 13(4):639. https://doi.org/10.3390/cancers13040639

Sanghvi, Viraj R., Prathibha Mohan, Kamini Singh, Linlin Cao, Marjan Berishaj, Andrew L. Wolfe, Jonathan H. Schatz, Nathalie Lailler, Elisa de Stanchina, Agnes Viale, and et al. 2021. "NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy" Cancers 13, no. 4: 639. https://doi.org/10.3390/cancers13040639

Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., & Wendel, H.-G. (2021). NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. Cancers, 13(4), 639. https://doi.org/10.3390/cancers13040639